← Eichor
Study identifier: NCT06626139 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Investigating the Interaction of Psilocybin and Context of Its Administration in Healthy Volunteers

Condition: Healthy Participants With Lower-than-average Mental Well-being  ·  Sponsor: Robin Carhart-Harris, PhD, MA

PhasePhase 2
Planned participants120
Who can joinAll sexes, 21 Years to 70 Years
Healthy volunteersYes

About this study

One hundred twenty healthy participants, ages 21 to 70, who experience moderate-to-lower-than-average mental well-being will be evenly randomized into four different study arms, using a 2x2 factorial design. Depending on the study arm, participants will either receive an inactive placebo or up to 25mg psilocybin (oral dose), in one of two set and setting conditions; drug administration contexts that are predicted to modulate drug effects. The purpose of this study is to evaluate any interaction effects between an oral dose of psilocybin and the surrounding context (set and setting).

This description comes directly from the study's public registry record.

Talk to the study team

Hannes Kettner, MSc  ·  4158495452  ·  setandsetting@ucsf.edu

Avery Ostrand, MSc  ·  avery.ostrand@ucsf.edu

Always discuss trial participation with your own doctor first.

Locations (1)

UCSF Mission BaySan Francisco, California, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06626139